dr. leslie on the role of btk inhibitors in relapsed/refractory mcl
Published 4 years ago • 48 plays • Length 1:47Download video MP4
Download video MP3
Similar videos
-
1:56
dr. rule on the role of btk inhibitors in mcl
-
1:00
dr. leslie on the utility of btk inhibitors in b-cell malignancies
-
7:11
selection of a btk inhibitor in relapsed/refractory mcl
-
1:22
dr. leslie on sequencing zanubrutinib in mcl
-
1:29
dr. leslie on the role of zanubrutinib in mcl
-
1:28
dr. ma on the utility of btk inhibitors in relapsed/refractory cll
-
0:58
dr. leslie on the benefits with zanubrutinib in mcl
-
1:21
dr koff on the role of covalent btk inhibitors and pirtobrutinib in mcl
-
5:59
differentiating btk inhibitor mechanisms of action in mcl
-
4:16
mcl: differences in trial design between btk inhibitors
-
2:22
dr. leslie on the development of car t-cell therapy in dlbcl and mcl
-
1:46
btk inhibitors continue to improve survival in mantle cell lymphoma
-
0:41
dr. goy on the potential utility of btk inhibitors as maintenance in mcl
-
0:55
dr. smith on safety profiles of btk inhibitors in mcl
-
1:35
dr. lee on b-cell receptor targeting in relapsed/refractory mcl
-
2:40
btk inhibitors for r/r mcl: current uses and insights from the vipor study
-
2:16
dr. ruan discusses btk inhibitors in mcl
-
1:13
dr. leslie on remaining questions address in mcl
-
2:08
administration of btk inhibitors for mantle cell lymphoma